Cas:64509-07-5 [(1E,3E)-octadeca-1,3-dienyl] dihydrogen phosphate manufacturer & supplier

Chemical Name:[(1E,3E)-octadeca-1,3-dienyl] dihydrogen phosphate

CAS.NO:64509-07-5

Synonyms:Octadecadienyl dihydrogen phosphate;EINECS 264-933-7

Molecular Formula:C₁₈H₃₅O₄P

Molecular Weight:346.44200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:475.1ºC at 760 mmHg

Density:1.023 g/cm3

Index of Refraction:1.486

PSA:76.57000

Exact Mass:346.22700

LogP:6.25680

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Octadecadienyl dihydrogen phosphate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 264-933-7 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Octadecadienyl dihydrogen phosphate Use and application,EINECS 264-933-7 technical grade,usp/ep/jp grade.

Related News: The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. [(1E,3E)-octadeca-1,3-dienyl] dihydrogen phosphate manufacturer On Friday, the US Association of Flight Attendants — which represents 50,000 flight attendants across 20 airlines — called on the government to work with airlines to discontinue all travel to China until the spread of coronavirus is contained. [(1E,3E)-octadeca-1,3-dienyl] dihydrogen phosphate supplier The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island. [(1E,3E)-octadeca-1,3-dienyl] dihydrogen phosphate vendor The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. [(1E,3E)-octadeca-1,3-dienyl] dihydrogen phosphate factory First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s.